Benitec Biopharma Inc.
For the period ended Sep 30, 2026. Filed Nov 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 13, 2026
BNTC$9.04-0.6%Stored close · as of Nov 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
Checking your notes…
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Loss | Equity | |
| Balance at June 30, 2025 | 26,250,469 | $2 | $326,308 | $(228,176) | $(839) | $97,295 |
| Stock-based compensation | — | — | 5,180 | — | — | 5,180 |
| Foreign currency translation gain | — | — | — | — | 89 | 89 |
| Net loss | — | — | — | (8,965) | — | (8,965) |
| Balance at September 30, 2025 | 26,250,469 | $2 | $331,488 | $(237,141) | $(750) | $93,599 |
| Common Stock · AdditionalPaid-in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Loss | Equity | |
| Balance at June 30, 2026 | 34,416,834 | $3 | $451,695 | $(273,722) | $(963) | $177,013 |
| Stock-based compensation | — | — | 5,508 | — | — | 5,508 |
| Exercise of pre-funded warrants | 465,892 | 1 | — | — | — | 1 |
| Exercise of options | 6,587 | — | 34 | — | — | 34 |
| Foreign currency translation gain | — | — | — | — | 16 | 16 |
| Net loss | — | — | — | (12,925) | — | (12,925) |
| Balance at September 30, 2026 | 34,889,313 | $4 | $457,237 | $(286,647) | $(947) | $169,647 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.